Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

How I Treat: An Older Patient With High-Risk CLL With Deletion 17p

07/15/2024

John Allan, MD, discusses the treatment regimen he chose for an older patient with high-risk chronic lymphocytic leukemia with deletion 17p who has chronic medical issues such as atrial fibrillation and diabetes.

John Allan, MD, discusses the...

07/15/2024

Oncology

Conference Coverage

Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment

04/10/2024

Featuring John Allan, MD

John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.

John Allan, MD, compares the use...

04/10/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Influence of Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia

04/06/2024

Featuring John Allan, MD

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, John Allan, MD, shares expert insight on the impact targeted agents have in the treatment of CLL, focusing particularly on frontline therapy.

At the 2024 Great Debates &...

04/06/2024

Oncology

Conference Coverage

Novel Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

03/20/2024

Featuring John Allan, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.

At the Lymphoma, Leukemia &...

03/20/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Evaluating Effects of Racial Disparities on the Treatment of Patients With Chronic Lymphocytic Leukemia

12/12/2023

Fetauring Ira L Zackon, MD

At the 65th ASH Annual Meeting, Ira L Zackon, MD, presented real-world data from a large community oncology setting on the racial disparities observed in chronic lymphocytic leukemia treatment.

At the 65th ASH Annual Meeting,...

12/12/2023

Oncology

Conference Coverage

Extended Follow-up of ALPINE Study Confirms Zanubrutinib Yields Progression-Free Survival Benefit vs Ibrutinib for R/R CLL/SLL

12/11/2023

Featuring Jennifer Brown, MD

At the 65th ASH Annual Meeting, Jennifer R Brown, MD, PhD, presented follow-up data which found that zanubrutinib continued to be a more efficacious treatment than ibrutinib for patients with R/R chronic lymphocytic leukemia/small lymphocytic...

At the 65th ASH Annual Meeting,...

12/11/2023

Oncology

Conference Coverage

Analyzing Long-Term Outcomes of Ibrutinib Therapy for Patients With Chronic Lymphocytic Leukemia

12/11/2023

Featuring Adrian Wiestner, MD

At the 65th ASH Annual Meeting, Adrian Wiestner, MD, presented long-term follow-up data on a phase 2 study assessing the efficacy, safety, and depth of response of ibrutinib therapy for patients with CLL.

At the 65th ASH Annual Meeting,...

12/11/2023

Oncology

Conference Coverage

Importance of Assessing Minimal Residual Disease for R/R CLL Treatment

12/10/2023

Featuring Paolo Ghia, MD, PhD

At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, discusses the importance of assessing minimal residual disease when treating patients with relapsed/refractory chronic lymphocytic leukemia, particularly those with high-risk disease.

At the 65th ASH Annual Meeting,...

12/10/2023

Oncology

Conference Coverage

Frontline Ibrutinib Plus Venetoclax Treatment Demonstrates Lasting Efficacy for Patients With CLL/SLL

12/10/2023

Featuring Paolo Ghia, MD, PhD

At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, highlights findings from up to 5 years of follow-up of the CAPTIVATE study, which demonstrates the durable efficacy of ibrutinib plus venetoclax as a first-line treatment among patients...

At the 65th ASH Annual Meeting,...

12/10/2023

Oncology

Videos

Future Potential of Noncovalent BTK Inhibitor Therapy for Patients With Chronic Lymphocytic Leukemia

08/17/2023

Featuring Susan M. O'Brien, MD

Featuring Susan M. O'Brien, MD ...

Susan M. O'Brien, MD, discusses the possible applications of pirtobrutinib, a noncovalent BTK inhibitor, for the treatment of patients with CLL.

Susan M. O'Brien, MD, discusses...

08/17/2023

Oncology

Chronic Lymphocytic Leukemia Excellence Forum

Specialties

Events

Year Round Education

HMP Global Products